Molecular target
Melatonin Receptor (MT1 / MT2)
G-protein-coupled receptors mediating melatonin's circadian and sleep-onset effects. Targeted by melatonin itself and by ramelteon (MT1/MT2 agonist hypnotic). Some plant compounds (8-prenylnaringenin in hops) have reported melatonin-receptor activity.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Melatonin Receptor (MT1 / MT2)
These medications have Melatonin Receptor (MT1 / MT2) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on Melatonin Receptor (MT1 / MT2)
Each plant below contains a named compound documented to act on Melatonin Receptor (MT1 / MT2). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- MelatoninIndoleamine
Cherry-derived melatonin is proposed to act via MT1/MT2 melatonin receptors; urinary melatonin metabolite elevation was reported in a randomised crossover study following tart cherry juice consumption.